Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

66.04 +0.13 (+0.20%)
Delayed Quote Updated: 2:29 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 852,149
Open 65.73
Bid (Size) 65.98 (200)
Ask (Size) 66.11 (100)
Prev. Close 65.91
Today's Range 65.30 - 67.27
52wk Range 53.57 - 88.31
Shares Outstanding 95,640,600
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference ↗
Cytokinetics (NASDAQ:CYTK) executives outlined the company’s commercial expansion plans, cardiovascular pipeline and business-development priorities during a Bernstein investor symposium, highlighting... 
Via MarketBeat
News headline image
If You Invested $1000 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today ↗
Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 10.3% on an annualized basis producing an average annual return of 23.89%. Currently, Cytokinetics has a market... 
Via Benzinga

Performance

YTD
+7.0%
+7.0%
1 Month
-6.9%
-6.9%
3 Month
-22.5%
-22.5%
6 Month
-0.9%
-0.9%
1 Year
+20.2%
+20.2%

More News

Read More
News headline image
If You Invested $100 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today ↗
Via Benzinga
News headline image
Cytokinetics’ Aficamten Hits Dual Phase III Endpoints in Non-Obstructive HCM ↗
Via MarketBeat
Cytokinetics (NASDAQ:CYTK) Beats Q2 Estimates on Strong MYQORZO Launch ↗
Via Chartmill
Cytokinetics Inc. (NASDAQ:CYTK) Scores Strong Setup Quality for a Potential Breakout ↗
Via Chartmill
Cytokinetics Inc (NASDAQ:CYTK) Reports Strong Q4 Revenue Beat Amid Deepening Losses and Negative Market Reaction ↗
Via Chartmill
News headline image
Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700 ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cytokinetics (CYTK) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings Economy
News headline image
Cytokinetics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Here's How Much $100 Invested In Cytokinetics 10 Years Ago Would Be Worth Today ↗
Via Benzinga
News headline image
Prediction: U.S. Small-Cap Stocks Will Beat Large Caps for 10 Years ↗
Via The Motley Fool
Topics ETFs
News headline image
What This Cytokinetics Insider Sale Might Mean With the Stock Up 110% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise ↗
Via MarketBeat
News headline image
Cytokinetics (CYTK) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Derivatives ETFs Regulatory Compliance
News headline image
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year ↗
Via The Motley Fool
News headline image
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cytokinetics (CYTK) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO
Via MarketMinute
Topics Intellectual Property

Frequently Asked Questions

Is Cytokinetics, Incorporated - Common Stock publicly traded?
Yes, Cytokinetics, Incorporated - Common Stock is publicly traded.
What exchange does Cytokinetics, Incorporated - Common Stock trade on?
Cytokinetics, Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cytokinetics, Incorporated - Common Stock?
The ticker symbol for Cytokinetics, Incorporated - Common Stock is CYTK on the Nasdaq Stock Market
What is the current price of Cytokinetics, Incorporated - Common Stock?
The current price of Cytokinetics, Incorporated - Common Stock is 66.04
When was Cytokinetics, Incorporated - Common Stock last traded?
The last trade of Cytokinetics, Incorporated - Common Stock was at 10/01/26 02:29 PM ET
What is the market capitalization of Cytokinetics, Incorporated - Common Stock?
The market capitalization of Cytokinetics, Incorporated - Common Stock is 6.32B
How many shares of Cytokinetics, Incorporated - Common Stock are outstanding?
Cytokinetics, Incorporated - Common Stock has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.